New Platform Matches Patients to Precision Oncology Trials
WEDNESDAY, Oct. 19, 2022 (HealthDay News) -- A new open-source platform speeds matching of patients to precision medicine (PM) oncology trials, according to a study published online Oct. 6 in npj Precision Oncology.
Harry Klein, Ph.D., from Dana-Farber Cancer Institute in Boston, and colleagues developed MatchMiner, an open-source platform to computationally match genomically profiled cancer patients to PM trials. The MatchMiner capabilities, its deployment at the Dana-Farber Cancer Institute, and its impact on PM trial enrollment are characterized in the study.
The researchers report that from March 2016 through March 2021, 354 PM trials containing a broad range of genomic and clinical eligibility criteria were curated. MatchMiner facilitated 166 trial consents for 159 patients. MatchMiner had a shorter time from genomic sequencing report date to trial consent (55 days shorter; 22 percent earlier) versus patients consented through non-MatchMiner means.
“The combination of this growing body of genomic data and increasing number of precision medicine trials has created a kind of disconnect: finding the right trial for each patient can be a difficult task,” one author said in a statement. “MatchMiner helps bridge that gap.”
Related Posts
Chicken Pox (Children)
What is chicken pox? Chicken pox is a disease marked by an itchy rash that...
Parents Say Too Much Screen Time, Social Media Are Biggest Concerns
WEDNESDAY, August 23, 2023 (HealthDay News) -- Overuse of devices, screen time,...
En Canadá, un programa que suministra opioides seguros a los adictos salva vidas
MARTES, 20 de septiembre de 2022 (HealthDay News) -- Mientras las muertes por...
Pfizer to Seek FDA Approval of Boosters for Teens Ages 16-17
TUESDAY, Nov. 30, 2021 (HealthDay News) -- Pfizer Inc. is expected to seek...